The disruption everyone fears is the best opening the underdogs have had in a generation.
Years ago, during annual brand planning while working in pharma and leading a COE, an executive asked a question I’ve never forgotten: without changing the revenue goals and spend, how would this brand survive the elimination of DTC advertising in general or TV only?
It was a thought experiment with low odds, and that was the point. It attacked what we all took as a given: that you buy reach to drive revenue at scale, and that the biggest reach channel was just part of the furniture. Take it away, keep the number, and every comfortable assumption is back on the table. I found it intriguing then. It is no longer hypothetical now.
For almost thirty years, pharma marketing ran on a simple, unfair rule: the brand with the biggest broadcast budget won the patient. If you couldn’t afford a Super Bowl spot, you weren’t really in the conversation. That rule is cracking. If you run a smaller or emerging brand, you should be the first to cheer.
What’s breaking
The US is one of only two countries that allow DTC prescription advertising,[1] and more than $10.1 billion a year flows into it.[2] The entire 60-second TV spot rests on one mechanism: broadcast ads state only the major risks aloud and point you elsewhere for the rest. That trade-off, in place since the late 1990s, is why drug ads are watchable.
In September 2025, FDA and HHS moved to take it away.[3] By the agencies’ own admission, a spot reading every contraindication would run minutes, not seconds. Before this mechanism existed, broadcast drug ads were rare for exactly that reason. This is not a tweak. It is a question of whether the format survives.
And it is two fronts, not one. In Congress, the Responsibility in Drug Advertising Act would bar DTC for a new drug’s first three years on the market.[4] Both efforts face First Amendment headwinds and may not pass. But the intent is clear, and intent is what you plan against: HHS now blames DTC for roughly 31% of the rise in drug spending since 1997.[5]
So here is the provocative part. The most exposed brands aren’t the small ones. They’re the giants: the blockbuster franchises with hundreds of millions in TV spend, the most inertia to unwind, and agencies built around a channel going dark. Their megaphone is breaking.
The void won’t be filled by better TV
Every brand reaches for the nearest substitute: connected TV, streaming, social, influencer. Most miss the point. The same 2025 action named “closing digital loopholes” and social media oversight.[6] CTV gives sharper targeting but inherits the disclosure burden breaking broadcast.
Short-form is the real trap. A Reel, a TikTok, a YouTube Short is built for seconds, sound on, thumb already moving. You cannot fit a major-risk statement into fifteen vertical seconds without killing the thing that makes it work. The format that looks most like cheap scale is the one you can least use for a branded claim. Branded social is not the escape hatch. It is the next room the squeeze walks into.
Where social earns its place is the one job that doesn’t trip the rules: unbranded education. Disease awareness, patient community, help-seeking content that never pairs a drug name with a claim carries no fair-balance burden, because it isn’t a drug ad. Use social to build demand you can actually capture. Don’t ask it to make the claim TV used to make for you.
But can the math still work?
The question your CFO asks first. Look at Vertex. Its cystic fibrosis franchise drove $11.02 billion in 2024, with Trikafta alone at $8.9 billion the year before, on essentially no consumer TV.[7] The CF population is small and identifiable. When a label expansion adds a few hundred eligible patients, you don’t buy a Super Bowl to find them. You reach them through specialists, advocacy, and patient support. Precision, not reach.
So the honest answer is another question: how findable is your patient? The more identifiable they are, the easier broadcast is to replace and the better your return without it. That names the seam in my own headline: yes, the three-year rule targets new launches, and emerging brands are new launches. But a brand whose patient is findable never needed the broadcast launch the rule takes away.
Now what
The rulemaking will take a year or more, with comment periods and a constitutional fight. That is not a reason to wait. It is your opportunity. Build first-party data, stand up unbranded education, deepen point of care, and fix your measurement: the no-regrets moves that pay off however the rule lands. The brand that can’t measure impact will panic when broadcast wobbles. The one that can will arbitrage the disruption while the giants are still in meetings.
For thirty years the rule favored the big. The new one favors the brand closest to the patient, that owns its relationships, and won’t confuse being loud with being effective. That was never the giants. It was always you.
The brands that map their options are the ones still standing when the changes happen.
More Perspectives
The first conversation is twenty-five minutes — a diagnostic, not a pitch.
Start a conversation today
We listen for the real problem — how you got here, what you’ve tried, what success looks like — then come back with a structured read. The gap between the call and the response is where the senior judgment gets applied.